steady as she goes
The Company remains in dialogue with a number of pharmaceutical companies, which could lead to multiple
international licensing opportunities. Vectus continues to receive enquiries from industry participants who
recognise the significant potential of the Company’s novel anti-fibrotic compounds.
this was the most interesting statement for me...
Ann: Quarterly Activities Report & Appendix 4C, page-2
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add VBS (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
8.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $4.256M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 13462 | 7.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.0¢ | 114426 | 1 |
View Market Depth
| Last trade - 16.12pm 13/09/2024 (20 minute delay) ? |
| VBS (ASX) Chart |
Day chart unavailable